Core Viewpoint - Fujilai's stock has shown significant growth this year, with a year-to-date increase of 52.95%, indicating strong market performance and investor interest [1][2]. Company Overview - Fujilai Pharmaceutical Co., Ltd. is located in Changshu, Jiangsu Province, and was established on November 27, 2000. The company went public on March 29, 2022, and specializes in the research, production, and sales of active pharmaceutical ingredients and health product raw materials [1]. - The main revenue sources for Fujilai include: 66.02% from alpha-lipoic acid products, 14.86% from carnosine products, 11.88% from etoricoxib, 5.95% from phosphatidylcholine products, and 1.29% from other supplementary products [1]. Financial Performance - For the period from January to September 2025, Fujilai achieved an operating income of 323 million yuan, representing a year-on-year growth of 3.23%. The net profit attributable to shareholders was 73.40 million yuan, showing a substantial increase of 430.16% [2]. - Since its A-share listing, Fujilai has distributed a total of 153 million yuan in dividends, with 116 million yuan distributed over the past three years [3]. Shareholder Information - As of October 20, 2025, Fujilai had 11,000 shareholders, a decrease of 0.47% from the previous period. The average number of circulating shares per shareholder increased by 0.47% to 8,083 shares [2]. - Among the top ten circulating shareholders, Galaxy Kangle Stock A (519673) is the ninth largest, holding 178,100 shares as a new shareholder [3].
富士莱涨2.13%，成交额4283.46万元，主力资金净流出45.78万元